{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T21:04:06Z","timestamp":1757624646670,"version":"3.44.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009594","name":"University of P\u00e9cs","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009594","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Potential beneficial effects of teleprogramming on the efficacy of deep brain stimulation (DBS) have not been studied. We aimed to explore the effects of travel distance on the outcome of DBS in Parkinson\u2019s disease (PD). We retrospectively analyzed travel- and visit-related data of PD patients treated with DBS. Comparing the first-year and five-year outcomes of far-living patients (&gt;\u200950\u00a0km) having the desired number of follow-up visits (<jats:italic>n<\/jats:italic>\u2009=\u200974) to those of far-living subjects having less visits than optimal (<jats:italic>n<\/jats:italic>\u2009=\u200954), patients with desired number of visits had better global health-related quality of life according to summary indexes of disease-specific and non-specific scales at five years. Far-living patients with desired number of visits had larger decrease in Parts II, III and IV of the Movement Disorder Society-sponsored Unified Parkinson\u2019s Disease Rating Scale from baseline to the five-year follow-up and more simplified antiparkinsonian medication treatment. Even 40% of PD patients with DBS who live far from the movement disorder center may have less in-person visits than optimal and be on the risk of having worse long-term outcome of DBS than could be achieved. Teleprogramming may help maintaining the long-term efficacy of stimulation in this group of patients.<\/jats:p>","DOI":"10.1038\/s41598-025-14519-6","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T07:34:10Z","timestamp":1755329650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Travel distance may have a negative impact on the outcome of deep brain stimulation in Parkinson\u2019s disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Hemeda","family":"Sahar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e1vid","family":"Pint\u00e9r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Pint\u00e9r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istv\u00e1n","family":"Bal\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f3zsef","family":"Janszky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"issue":"9","key":"14519_CR1","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa060281","volume":"355","author":"G Deuschl","year":"2006","unstructured":"Deuschl, G. et al. A randomized trial of deep-brain stimulation for parkinson\u2019s disease. N Engl. J. Med. 355 (9), 896\u2013908 (2006).","journal-title":"N Engl. J. Med."},{"issue":"19","key":"14519_CR2","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1056\/NEJMoa063618","volume":"355","author":"A Kupsch","year":"2006","unstructured":"Kupsch, A. et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Eng. J. Med. 355 (19), 1978\u20131990 (2006).","journal-title":"N Eng. J. Med."},{"key":"14519_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.parkreldis.2017.03.017","volume":"40","author":"RE Wharen Jr","year":"2017","unstructured":"Wharen, R. E. Jr et al. Thalamic DBS with a constant-current device in essential tremor: A controlled clinical trial. Parkinsonism Relat. Disord. 40, 18\u201326 (2017).","journal-title":"Parkinsonism Relat. Disord"},{"issue":"6","key":"14519_CR4","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/mds.28098","volume":"35","author":"J Zhang","year":"2020","unstructured":"Zhang, J. et al. Implementation of a novel Bluetooth technology for remote deep brain stimulation programming: the Pre- and Post-COVID-19 Beijing experience. Mov. Disord. 35 (6), 909\u2013910 (2020).","journal-title":"Mov. Disord"},{"issue":"2","key":"14519_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/ner.13274","volume":"24","author":"C Zhang","year":"2021","unstructured":"Zhang, C. et al. Utility of deep brain stimulation telemedicine for patients with movement disorders during the COVID-19 outbreak in China. Neuromodulation 24 (2), 337\u2013342 (2021).","journal-title":"Neuromodulation"},{"issue":"6","key":"14519_CR6","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.3171\/2020.9.FOCUS20666","volume":"49","author":"Z Lin","year":"2020","unstructured":"Lin, Z. et al. Deep brain stimulation telemedicine programming during the COVID-19 pandemic: treatment of patients with psychiatric disorders. Neurosurg. Focus. 49 (6), E11 (2020).","journal-title":"Neurosurg. Focus"},{"issue":"1","key":"14519_CR7","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1038\/s41598-022-06098-7","volume":"12","author":"P Silburn","year":"2022","unstructured":"Silburn, P. et al. Rapid development of an integrated remote programming platform for neuromodulation systems through the biodesign process. Sci. Rep. 12 (1), 2269 (2022).","journal-title":"Sci. Rep."},{"key":"14519_CR8","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/j.wneu.2020.12.030","volume":"147","author":"Y Ma","year":"2021","unstructured":"Ma, Y. et al. Application of remote deep brain stimulation programming for parkinson\u2019s disease patients. World Neurosurg. 147, e255\u2013e261 (2021).","journal-title":"World Neurosurg."},{"key":"14519_CR9","unstructured":"Parmar, A. FDA approval brings remote programming for Abbott\u2019s deep brain stimulation device. MedCity News. ; (2021). https:\/\/medcitynews.com\/2021\/03\/fda-approval-brings-remote-programming-for-abbotts-deep-brain-stimulation-device\/ Accessed: January 7, 2022."},{"key":"14519_CR10","doi-asserted-by":"crossref","unstructured":"Vedam-Mai, V. et al. Proceedings of the Eight Annual Deep Brain Stimulation Think Thank: Advances in Optogenetics, Ethical Issues Affecting DBS Research, Neuromodulatory Approaches for Depression, Adaptive Neurostimulation, and Emerging DBS Technologies. Front Hum Neurosci. ; 15:644593. (2021).","DOI":"10.3389\/fnhum.2021.765150"},{"issue":"1","key":"14519_CR11","doi-asserted-by":"publisher","first-page":"17420","DOI":"10.1038\/s41598-022-22206-z","volume":"12","author":"D Pinter","year":"2022","unstructured":"Pinter, D., Jardahazi, E., Janszky, J. & Kovacs, N. Potential clinical and economic benefits of remote deep brain stimulation programming. Sci. Rep. 12 (1), 17420 (2022).","journal-title":"Sci. Rep."},{"issue":"1\u20132","key":"14519_CR12","first-page":"1","volume":"48","author":"K Horvath","year":"2017","unstructured":"Horvath, K. et al. Changes in quality of life in parkinson\u2019s disease: how large must they be to be. Relevant? Neuroepidemiology. 48 (1\u20132), 1\u20138 (2017).","journal-title":"Relevant? Neuroepidemiology"},{"issue":"1","key":"14519_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11136-016-1428-x","volume":"26","author":"Y Xin","year":"2017","unstructured":"Xin, Y. & McIntosh, E. Assessment of the construct validity and responsiveness of preference \u2013 based quality of life measures in people with parkinson\u2019s: a systematic review. Qual. Life Res. 26 (1), 1\u201323 (2017).","journal-title":"Qual. Life Res."},{"issue":"1","key":"14519_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks, R. EuroQol: the current state of play. Health Policy. 37 (1), 53\u201372 (1996).","journal-title":"Health Policy"},{"issue":"3","key":"14519_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group. EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy. 16 (3), 199\u2013208 (1990).","journal-title":"Health Policy"},{"issue":"7\u20138","key":"14519_CR16","first-page":"245","volume":"67","author":"N Kovacs","year":"2014","unstructured":"Kovacs, N. et al. [The impact of levodopa-carbidopa intestinal gel on health-related quality of life in parkinson\u2019s disease]. Ideggyogy Sz. 67 (7\u20138), 245\u2013250 (2014).","journal-title":"Ideggyogy Sz."},{"key":"14519_CR17","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/j.wneu.2019.01.132","volume":"125","author":"A Gorecka-Mazur","year":"2019","unstructured":"Gorecka-Mazur, A. et al. Activities of daily living and their relationship to Health-Related quality of life in patients with Parkinson disease after subthalamic nucleus deep brain stimulation. World Neurosurg. 125, e552\u2013e562 (2019).","journal-title":"World Neurosurg."},{"issue":"2","key":"14519_CR18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/archneurol.2010.260","volume":"68","author":"JM Bronstein","year":"2011","unstructured":"Bronstein, J. M. et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch. Neurol. 68 (2), 165 (2011).","journal-title":"Arch. Neurol."},{"issue":"15","key":"14519_CR19","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/mds.21652","volume":"22","author":"F Valldeoriola","year":"2007","unstructured":"Valldeoriola, F. et al. Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced parkinson\u2019s disease. Mov. Disord. 22 (15), 2183\u20132191 (2007).","journal-title":"Mov. Disord"},{"key":"14519_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.parkreldis.2022.01.017","volume":"96","author":"CD Esper","year":"2022","unstructured":"Esper, C. D. et al. Necessity and feasibility of remote tele-programming of deep brain stimulation system in parkinson\u2019s disease. Parkinsonism Relat. Disord. 96, 38\u201342 (2022).","journal-title":"Parkinsonism Relat. Disord"},{"key":"14519_CR21","doi-asserted-by":"crossref","unstructured":"Deli, G. et al. Deep Brain Stimulation Can Preserve Working Status in Parkinson\u2019s Disease. Parkinsons Dis. ; 2015:936865. (2015).","DOI":"10.1155\/2015\/936865"},{"issue":"5\u20136","key":"14519_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1159\/000455208","volume":"77","author":"A Juhasz","year":"2017","unstructured":"Juhasz, A. et al. How efficient is subthalamic deep brain stimulation in reducing dyskinesia in parkinson\u2019s disease?? Eur. Neurol. 77 (5\u20136), 281\u2013287 (2017).","journal-title":"Eur. Neurol."},{"issue":"2","key":"14519_CR23","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.neurom.2022.01.006","volume":"26","author":"D Pinter","year":"2023","unstructured":"Pinter, D. et al. Antiparkinsonian drug reduction after directional versus omnidirectional bilateral subthalamic deep brain stimulation. Neuromodulation 26 (2), 374\u2013381 (2023).","journal-title":"Neuromodulation"},{"key":"14519_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.parkreldis.2018.08.018","volume":"58","author":"A Makkos","year":"2019","unstructured":"Makkos, A. et al. Minimal clinically important difference for the historic parts of the unified dyskinesia rating scale. Parkinsonism Relat. Disord. 58, 79\u201382 (2019).","journal-title":"Parkinsonism Relat. Disord"},{"issue":"8","key":"14519_CR25","doi-asserted-by":"publisher","first-page":"875","DOI":"10.2165\/00019053-200119080-00009","volume":"19","author":"T Shimbo","year":"2001","unstructured":"Shimbo, T., Hira, K., Takemura, M. & Fukui, T. Cost-effectiveness analysis of dopamine agonists in the treatment of parkinson\u2019s disease in Japan. Pharmacoeconomics 19 (8), 875\u2013886 (2001).","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"14519_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2165\/00019053-200321020-00004","volume":"21","author":"M Iskedjian","year":"2003","unstructured":"Iskedjian, M. & Einarson, T. R. Cost analysis of ropinirole versus Levodopa in the treatment of parkinson\u2019s disease. Pharmacoeconomics 21 (2), 115\u2013127 (2003).","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"14519_CR27","doi-asserted-by":"publisher","first-page":"14456","DOI":"10.1038\/s41598-018-32161-3","volume":"8","author":"D Su","year":"2018","unstructured":"Su, D. et al. Frequency-dependent effects of subthalamic deep brain stimulation on motor symptoms in parkinson\u2019s disease: a meta-analysis of controlled trials. Sci. Rep. 8 (1), 14456 (2018).","journal-title":"Sci. Rep."},{"issue":"2","key":"14519_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3233\/JPD-225060","volume":"13","author":"W Pirker","year":"2023","unstructured":"Pirker, W., Katzenschlager, R., Hallett, M. & Poewe, W. Pharmacological treatment of tremor in parkinson\u2019s disease revisited. J. Parkinsons Dis. 13 (2), 127\u2013144 (2023).","journal-title":"J. Parkinsons Dis."},{"issue":"7","key":"14519_CR29","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/mdc3.13032","volume":"7","author":"R Rajan","year":"2020","unstructured":"Rajan, R. et al. Anticholinergics May carry significant cognitive and gait burden in parkinson\u2019s disease. Mov. Disord Clin. Pract. 7 (7), 803\u2013809 (2020).","journal-title":"Mov. Disord Clin. Pract."},{"key":"14519_CR30","doi-asserted-by":"crossref","unstructured":"Su D, Chen H, Hu W, et al. Frequency-dependent effects of subthalamic deep brain stimulation on motor symptoms in Parkinson\u2019s disease: a meta-analysis of controlled trials. Sci Rep. 8 (1), 14456 (2018).","DOI":"10.1038\/s41598-018-32161-3"},{"key":"14519_CR31","doi-asserted-by":"crossref","unstructured":"Pirker W, Katzenschlager R, Hallett M, Poewe W. Pharmacological Treatment of Tremor in Parkinson\u2019s Disease Revisited. J Parkinsons Dis.  13 (2), 127-144 (2023).","DOI":"10.3233\/JPD-225060"},{"key":"14519_CR32","doi-asserted-by":"crossref","unstructured":"Pirker W, Katzenschlager R, Hallett M, Poewe W. Pharmacological Treatment of Tremor in Parkinson\u2019s Disease Revisited. J Parkinsons DiRajan R, Saini A, Verma B, et al. Anticholinergics May Carry Significant Cognitive and Gait Burden in Parkinson\u2019s Disease. Mov Disord Clin Pract. 7 (7), 803-809 (2020).","DOI":"10.1002\/mdc3.13032"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14519-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14519-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14519-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T14:53:11Z","timestamp":1757429591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14519-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14519"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-14519-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,8,16]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"DP, EP and NK received a research grant from Abbott Laboratories for conducting this study and preparing the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"29992"}}